Ophthalmic herpes simplex viral keratitis (HSVK) is responsible for a range of ocular manifestations from superficial epithelial disease to stromal keratitis and endotheliitis. The Herpetic Eye Disease Study (HEDS) has guided the management of herpetic eye disease for almost twenty years, but newer medications such as valacyclovir are now available and are considered to have better bioavailability than acyclovir. In this review, we examine the existing evidence on the pathogenesis of different HSVK disease modalities and the role of oral and topically administered antiviral drugs in the treatment of herpes simplex viral keratitis.
INTRODUCTION
Ocular herpes simplex infection and disease manifestation are a major cause of visual morbidity worldwide. It is estimated that 90% of adults are seropositive for the herpes simplex virus (HSV) antigen and approximately 500,000 cases of active ocular herpes simplex infection are seen per annum in the United States 1 . The prevalence of antibodies against the HSV in serum and tears increases with age and is related with reduced corneal sensation, neurotrophic keratitis and stromal opacities. 2 Interestingly, only 20-30% of herpes inoculated individuals develop clinical manifestations, with the majority of patients suffering from herpes labialis 3 .
Ocular infection is usually unilateral but bilateral cases occur at a rate of 1.3-12%
and are usually seen in younger patients 4 .
Herpes simplex infection can involve both anterior and posterior segments of the eye but most commonly it is seen as a corneal epithelial infection, namely a dendritic ulcer. HSV can affect any and all layers of the cornea but it is the relapsing and recurring stromal and endothelial disease that renders the greatest morbidity through corneal scarring and neovascularisation. Disciform keratitis accounts for
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approximately 2% of initial ocular HSV presentations but is responsible for 20-48%
of disease recurrences 1, 3, 5 .
Different treatment modalities against HSV have been developed to date and are also the field of current research in an effort to achieve better disease control and counteract resistance of the virus to currently used medication. Topical and systemic treatments exist, each one with specific mode of action and sometimes combination regimens are used to enhance the therapeutic outcomes.
THE STRUCTURE OF HSV
Herpes simplex virus exists in two forms: HSV-1 and HSV-2. HSV-1 is the more common sub-type manifesting in ocular infections 6 . HSV-1 has a linear double stranded DNA, comprising of 152 kb and approximately 80 genes 7 . The HSV-1 virion is approximately 120-300nm in size, consisting of an electroopaque core which contains the genome, a caspid or shell, a tegument and an envelope ( Figure 1 ).
Adherent to the capsid is the tegument, a layer that contains proteins essential for virus survival in host cells e.g. virion host shut-off protein (VHSP). HSV-1 has an outer lipid bi-layer, or envelope, with embedded glycoproteins (gB, gC, gD, gH) that facilitate virus to host cell attachment, fusion and permeability 8 .
Viral DNA transcription, replication and viral capsid assembly occur in the host nucleus with DNA polymerase essential for HSV-1 replication 9 . Synthesis of the tegument proteins occur in the cytoplasm 9 , with HSV viral replication taking between 18 and 20 hours 8, 9 . HSV infection can occur through direct cell to cell inoculation but HSV-1 can also be transported along sensory neurons and establish infection distant to its initial infection site. By assuming latency in sensory neurons or ganglia, HSV can re-emerge in an active form at a later date 8 .
LATENCY
HSV replication, usually leads to host cell death. However, in neuronal cells, viral replication is limited and is less destructive to its host cell, allowing the virus to remain dormant, reactivating at a later stage. This is known as latency. The HSV-1 genome exists in three states: linear, circular and concatemeric 10, 11 . A linear state is the preferred template for DNA transcription during replication. However, during viral latency, the HSV-1 genome is found in a circular form. Studies with mice have permitted the identification of viral transcripts called Latency-Associated-Transcripts (LATs) thought to be the key in inducing and maintaining viral latency. The LAT region has not been shown to encode for any proteins but is thought to be involved in neuronal survival, suppression of apoptosis, induction of latency and reactivation from latency 12 . During viral reactivation, expression of LATs decreases although the exact mechanism by which LATs function remains under investigation.
Ocular infection with HSV can occur directly through direct droplet spread or as a secondary infection, where an individual who has experienced previous exposure to HSV in non-ophthalmic parts of the trigeminal dermatome will subsequently manifest ocular HSV 13 .
HSV has been found in the brainstem and trigeminal ganglia (TG) and the latter is thought to be the principle site for HSV-1 latency. Virus is transported to the eye in a retrograde fashion along sensory axons although studies have also confirmed the presence of HSV in its latent form in the cornea but this still remains controversial 5, 14 .
The risk of HSV disease after primary infection is approximately 10% within the first year 5 . The trigger factors for reactivation are numerous and include physical stimuli such as corneal trauma through injury, surgery and excimer laser 15 . Other factors such as emotional stress, sun exposure and menstruation 16 are also recognised to trigger recurrent disease. The frequency of epithelial HSV recurrence is higher in patients with diabetes and atopic disease, corneal transplant patients, and immunocompromised individuals 17 .
PATHOGENESIS OF HSV INFECTION
HSV in general, can infect a variety of host cells like epithelial cells, fibroblasts, neurons and lymphocytes, thus is regarded as "broad cell tropic". The mechanism of viral entry varies depending on the cell type but mainly occurs in two different steps:
"In the first step, viral glycoproteins bind to the host cell receptors and in the second step, the viral envelope either fuses with the plasma membrane or undergoes endocytosis. Post fusion, viral nucleocapsid and tegument proteins are released into host cytoplasm, from where the proteins are transported into the nucleus by the dynein-dynactin protein complex. The capsids are propelled through the negative end of microtubules and released into nucleus through nuclear pore complexes.
Post infection into nucleus, host RNA polymerase II initiates viral gene expression.
HSV genes are expressed in a temporal regulated manner, in three distinct classes:
immediate early (IE/a), early (E/β) and late (L/y) genes. A procapsid is assembled inside the nucleus and packaged with viral DNA to form a mature capsid initially fuses with inner nuclear membrane (primary envelopment) to form an enveloped particle and gain fuses with outer nuclear membrane (de-envelopment) to release the capsids into cytoplasm. In the cytoplasm, capsids re-envelope (secondary envelopment), by budding into the Golgi compartment and are finally secreted from the infected cells." 18 ( Figure 2 )
Infection of the corneal cells with HSV provokes an interaction that induces a cascading immune response, rather than solely a direct cytolysis of corneal cells by the HSV. During HSV corneal infection there is an influx of polymorphonuclear (PMN) leucocytes, macrophages, natural killer cells and Langerhans cells into the underlying corneal stroma 19 . The influx of these immune cells is chemokine dependent. As few animal studies of corneal HSV infection employ recurrent infection models, little is understood about the mechanism of recurrent herpes simplex keratitis (HSK) 19 .
The pathogenesis of corneal fibrosis is partly understood. It is thought that recruited inflammatory cells release pro-inflammatory cytokines, chemokines and growth factors that initially aid in virus removal but then cause tissue destruction and scarring 5, 8 . Connective tissue in corneal scars is continually persistently remodeled but the lamellar re-organization remains different to that of unwounded corneal tissue 16 leading to increased light scatter and loss of transparency 20 .
HERPETIC EPITHELIAL KERATITIS
Corneal epithelium may be involved in up to two-thirds of cases with ocular involvement. In early stages, fine or coarse granular spots form a punctate epithelial corneal erosions or epithelial granularity may be present in the long-term. Also, some degree of anterior stromal reaction is common underlying the epithelial lesions. HSV epithelial keratitis is typically unilateral. The contralateral eye is infrequently affected, either simultaneously or subsequently in healthy individuals 8, 17 . This article is protected by copyright. All rights reserved. 
NEUROTROPHIC KERATOPATHY

HERPETIC STROMAL KERATITIS
For many years, stromal keratitis was considered to be solely an immune response to epithelial disease. More recently, it has been proposed that the pathogenesis lies in the immune response to HSV invading the anterior stroma, either through viral reactivation of latent HSV in sensory nerves or to the direct spread from epithelial infection 8, 23 .
Non 
ENDOTHELIITIS AND DISCIFORM KERATITIS
HSV may be associated with endothelial cell inflammation and consequent dysfunction 23 . Herpetic endotheliitis is typically described according to the pattern of endothelial disease: disciform, diffuse or linear 5, 8 . Disciform Keratitis is the most common form and is seen as a disc-shaped area of stromal oedema in the central or paracentral cornea. It usually results in full thickness stromal change and the cornea is often described as having a ground glass appearance. Keratic precipitates may be present (Figures 4a-4b ). Corneal thickness increases during active endotheliitis due to changes to the Na+/K+-ATPase pump density that regulates ion flux and thus water movement in and out of the cornea 23 . Corneal thickness is increased during the active phase of the disease and tends to normalize as the endotheliitis resolves 23, 24 . Stromal inflammation and stromal oedema are often difficult to differentiate.
It is unclear whether endotheliitis is caused by direct cytolytic attack of virus on the corneal endothelium or is the result of the cytokines and other mediators of the immune and inflammatory responses such as prostaglandins, leukotrienes and interleukins. However, literature data does not convincingly document that viral infection of the endothelium is the cause of the endothelial pathology observed and suggests that physical destruction of the endothelium is not likely to be the cause of oedema 23 .
PENETRATING KERATOPLASTY AND HSVK
The recurrence of herpetic disease in the donor cornea following penetrating keratoplasty (PK) is a significant problem and can precipitate corneal transplant rejection 8 . Reported recurrence rates vary but have been documented as high as 27% in the first year 5, 8 . The incidence of newly acquired HSV keratitis is 14-fold higher in transplant (PK patients or any transplant patients e.g. renal) patients compared with the normal population 25 .
Ocular herpes simplex was the cause of graft failure in 4% of the failed penetrating corneal grafts according to The Australian Corneal Graft Registry 26 .
The use of (topical or/and systemic) antivirals following penetrating keratoplasty is supported by several studies and is recommended for at least the first year postoperatively 27, 28 .
THE HED STUDY
The Herpetic Eye Disease Studies (HEDS) I and II were conducted prior to the availability of newer antiviral agents other than acyclovir but are still serving as guidance for the management of herpetic eye disease. The HED studies validated the use of topical corticosteroids in the treatment of herpes stromal keratitis and assessed the efficacy of oral acyclovir as an adjunct to treatment (Tables 1a-1b) 29, 30, 31, 32 .
The HED study I compared patients receiving topical corticosteroid (n = 57) versus a placebo medication (n =49). It was noted that the group treated with corticosteroids had a significantly reduced time to resolution and a risk reduction of 68% of persistent or progressive stromal keratouveitis 30, 32 . Topical corticosteroids are routinely used in the treatment of herpetic stromal keratitis.
The HED study I also evaluated effectiveness of oral acyclovir in the management of stromal herpes keratitis. Patients with disciform keratitis and necrotizing stromal keratitis were included. All patients received topical corticosteroid and trifluridine and were randomized to groups receiving oral acyclovir (at treatment dose: 400mg 5 times a day) or a placebo drug. Treatment failure (defined as no improvement, worsening of condition or an adverse event) was observed earlier, at 62 days, in the placebo group compared to the acyclovir group -where treatment failure occurred on average at 84 days. Additionally, visual acuity improvement was greater in the patients in the acyclovir group compared to the placebo group over the course of 6 months. However, these results were not statistically significant and the use of oral acyclovir as an adjunct to topical steroid therapy remains controversial 30, 31 . Despite this, acyclovir is often used alongside topical steroid therapy in the treatment of stromal keratitis.
Another part of the HEDS I was to look into the benefit of adding oral acyclovir to a regimen of topical prednisolone phosphate and trifluridine for the treatment of HSV iridocyclitis. Treatment failure occurred in 50% of the 22 patients in the acyclovirtreated group and in 68% of the 28 patients in the placebo group. Although the results of this study were not statistically conclusive because of the small number of patients, they suggested that there is benefit of oral acyclovir in the treatment of HSV iridocyclitis 30 .
With regard to disease recurrence, the HED study II found that oral acyclovir prophylaxis at a low dose (400mg twice a day), significantly reduced HSV recurrence rates compared to placebo and was particularly important to the subgroup of patient with a previous history of HSV stromal keratitis 29, 30 . In addition, HEDS II found no additional benefit of oral acyclovir in preventing HSV stromal keratitis or iritis when added to topical trifluridine in cases of HSV epithelial keratitis 30 . Finally, the same study looked into the role of external or behavioral factors on ocular recurrences of HSV infections concluding that no such an association exists 33 . The HED study was a multi-centered, randomized, placebo-controlled trial and has formed the foundation for the management of herpetic eye disease particularly stromal keratitis (see table 1 ) 29, 30, 31, 32 . Although there is no curative treatment for HSV infection and its elimination from the nervous system has not yet been possible, treatments are aimed at reducing corneal scarring and maintaining viral latency 30 .
USE OF SYSTEMIC ANTI-VIRAL MEDICATION IN HERPETIC EYE DISEASE
The HED study, found that patients treated with prophylactic oral acyclovir (400 mg twice a day) had a recurrence rate of HSVK of 19% compared with 32% in individuals treated with placebo 30 . As mentioned previously, the results of the HED study were published in 1994 31 , prior to the availability of newer acyclovir analogues such as valacyclovir that are currently thought to be more effective. To date there remains no randomized controlled trial examining the effectiveness of valacyclovir.
PHARMACOKINETICS
Acyclovir is nucleocide analogue that is selectively phosphorylated by the thymidine kinase (TK) of the HSV and herpes zoster virus (VZV) 38 . Acyclovir is also active, but to a lesser extent, against Epstein-Barr virus and cytomegalovirus 34 . It inhibits viral replication by acting as a substrate for DNA polymerase resulting in chain termination and preventing further elongation of the viral DNA chain 38, 39 . Acyclovir is highly specific for herpes virus infected cells and is known to be effective in the treatment of active herpes infection -both herpes simplex and herpes zoster-and in the suppression of latent disease 38 . The DNA polymerase of herpes simplex virus has a 10-to 30-fold greater affinity for acyclovir triphosphate than that of uninfected cells 40 . Acyclovir is only partially absorbed by the human gastrointestinal tract. Peak plasma concentrations are achieved approximately 1.5 hours after oral ingestion and have a half-life of 2-3 hours 41 . The bioavailability at therapeutic doses is limited at 20% and because of this, it needs to be to be administered in high doses and at high frequency 42, 43 .
Valacyclovir is the l-valyl ester of acyclovir. It is synthesized by the addition of an amino acid, L-valine, to the acyclovir molecule (Figures 5a-5b) 
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. It serves as a prodrug as it is rapidly converted to acyclovir and l-valine. The conversion of valacyclovir to acyclovir leads to an increased acyclovir bioavailability by 3-5 fold compared to oral acyclovir administration 36 . Unlike acyclovir which reaches a bioavailability of 10-20% due to its low absorption, acyclovir bioavailability after valacyclovir administration increases to more than 50%. 36 Maximum plasma concentration of acyclovir was seen after 2 hours of oral administration 41 . Studies comparing acyclovir and valacyclovir dosing found that in order to achieve a dose equivalent to 800mg of acyclovir 5 times a day, the treatment dose for herpes zoster infections, a dose of 500 mg twice a day or 250mg of valacyclovir 4 times a day would have to be administered 41 . Additionally, good drug delivery is achieved with valacyclovir, as it is almost fully converted to acyclovir during first pass metabolism; studies measuring valacyclovir concentrations in 24 hour urine collection estimated a loss of 1% unchanged valacyclovir 41 .
Studies with human gastrointestinal cell lines demonstrated an increase in mucosal
to serosal transport of valacyclovir compared to acyclovir, suggesting a carriermediated transport 35 . After the absorption of valacyclovir, the L-valine moiety is hydrolyzed to yield acyclovir. The metabolism of valacyclovir to acyclovir is thought to occur in the gut lumen ( Figure 6 ). The increased uptake and rapid hydrolysis results in a greater systemic acyclovir concentration. It has been reported that more than 95% of valacyclovir is converted to acyclovir 35 . Studies comparing the bioavailability of acyclovir after the administration of 1g dose of valacyclovir versus acyclovir showed this to be 54.2% and 15-30% respectively 35 . The high bioavailability of valacyclovir leads to plasma acyclovir levels comparable to those obtained with intravenous administration of acyclovir. Weller and associates found that 1000 mg of valacyclovir given four times a day resulted in equivalent acyclovir levels to intravenous acyclovir administration at doses of 5mg/kg every 8 hours.
Higher plasma levels comparable to intravenous doses of 10 mg/kg every eight hours can be achieved with higher doses of valacyclovir such as 2000 mg four times a day 35 .
SAFETY PROFILE OF ORAL ANTIVIRALS
Valacyclovir and acyclovir are well-tolerated drugs. The most commonly reported side effect is nausea, vomiting, headache and gastro-intestinal upset. Dosage modification is required in patients with renal impairment as there is a risk of nephrotoxicity 34 . It has been suggested that the lower peak plasma concentrations associated with oral valacyclovir treatment may reduce the risk of renal side-effects compared to acyclovir 44 .
ANIMAL MODELS IN HSVK
Animal models have been used to study the pathogenesis of HSVK and to test the effects and efficacy of novel therapies, although it is recognized that there may be significant limitations in extrapolating findings of these studies to humans 11 .
Asbell examined the recurrence rate of HSVK in rabbits after undergoing excimer laser photokeratectomy and also studied the recurrence rates in rabbits treated with different doses of valacyclovir 16 . It was reported that excimer laser photokeratectomy was a triggering factor for HSVK reactivation and a recurrence rate of 67% was observed 16 . Most importantly, this study found that reactivation rates were reduced in the valacyclovir treated group of rabbits and that the recurrence rates of disease were further reduced with increased drug doses 16 . More specifically, 50mg/kg per day of valacyclovir reduced recurrence rates to 50% and a dose of 100mg/kg of Valacyclovir per day reduced recurrence rates further to 17%.
With a dose of 150mg/kg of valacyclovir per day, no disease recurrences were observed 16 .
Kumar et al showed that HSV-1 DNA shedding in rabbit tears decreased with increasing doses of valacyclovir. However, doses greater than the human equivalent to 500mg valacyclovir OD were needed to suppress DNA shedding 44 .
In a study performed in New Zealand Albino rabbits, Dias et al showed that acyclovir can be detected in the aqueous humor following intravenous acyclovir and valacyclovir administration 45 .
HUMAN STUDIES
Prior to the advent of antivirals use in HSK, the mainstay of treatment involved to rub off the infected surface of the eye. Various methods of curettage, cauterisation, and chemoablation were used to remove the corneal epithelium. Potential shortcomings of debridement included damage to Bowman"s layer and exacerbation of corneal inflammation and opacification. Epithelial keratitis recurred after debridement, presumably due to viral shedding or infection of remaining cells of the ocular surface. With the continuous emergence of the various antivirals, using a wiping method followed by an antiviral drug is not consistently better than just an antiviral medication. Compared to topical antiviral monotherapy, the combination of an antiviral agent with debridement has inconsistent effects on enhancing healing and improving outcomes 46 .
The efficacy of prophylactic valacyclovir in the prevention of HSV ocular recurrences was compared to that of acyclovir by Miserocchi el al 47 . He compared 26 immunocompetent patients in two treatment groups measuring disease recurrence over a 12-month period. Disease recurrence was 23.1% in both groups and there was no discrepancy in disease severity, frequency and adverse events 47 . He concluded that 500mg of Valacyclovir once a day was as effective as 400mg of acyclovir twice a day in preventing disease recurrence 47 .
Sozen et al in 2006 conducted a study of 28 patients with epithelial HSVK 48 . He noted that patients treated with valacyclovir (1gr twice a day) instead of acyclovir ointment (five times a day) healed faster 48 .
Higaki et al advocated the use of valacyclovir in patients intolerant to topical acyclovir and also observed that HSV DNA was undetectable after a week of treatment and coincided with healed epithelial disease 36 .
In a study looking at the ocular penetration of acyclovir after oral valacyclovir and intravenous acyclovir administration, Huynh et al found that orally administered valacyclovir quickly leads to substantial vitreous acyclovir concentrations in noninflamed human eyes 49 . It was reported that on average, the vitreous acyclovir levels were approximately 25% that of the serum levels. The time to maximum serum concentration of acyclovir after an oral dose of valacyclovir has been estimated at 2 hours 49 .
HSV ANTIVIRAL RESISTANCE
"Among immunocompetent patients, resistance to ACV is rare. Several reports have described prevalence below 1% in this population whereas prevalence of ACV resistance among immunocompromised patients is about 5%. 
TOPICAL ANTIVIRALS IN HERPETIC EYE DISEASE
Early generation drugs
The topical antiviral agents used against HSV have primarily been nucleoside analogues. They interrupt viral DNA synthesis by the irreversible binding of viral DNA polymerase within infected cells 51, 52 .
Early generation drugs included idoxuridine, iododesoxycytidine, vidarabine, and trifluridine. All of these drugs were effective in HSV keratitis but they also exhibited non-selective activity against DNA synthesis by inhibiting DNA replication of both normal and viral-infected cells; thus, resulting in cellular and ocular surface toxicity such as epithelial keratitis, ulceration, delayed wound healing, follicular and cicatricial conjunctivitis as well as punctal and canalicular stenosis. They also tended to have low bioavailability and as a result their use was limited as more effective and better-tolerated topical medications became available. However, "trifluridine, a synthetic pyrimidine nucleoside, was approved by the United States (US) Food and Drug Administration (FDA) as a 1% solution for treatment of HSV keratitis in 1980. It is administered every 2 hours, up to nine times a day and has become the most widely used topical antiviral agent for treatment of HSV keratitis in the US." 50 It was the only topical antiviral medication used in the HED studies despite the local toxic side effects that accompany its use.
"Acyclovir is another purine nucleoside analogue, but with selective inhibitory activity against HSV DNA polymerase. It is able to inhibit viral DNA synthesis without concomitantly interrupting uninfected host cells." 51 In Europe, acyclovir is available as a 3% ointment and it has become the first-line topical treatment for HSV epithelial keratitis in Europe and elsewhere outside of the US. It is used five times daily in the acute phase and it has been demonstrated to be effective against HSV keratitis. Local toxicity is less than that of the nonselective agents mentioned earlier but the ointment contains vaseline and can cause some discomfort and blurred vision, which may affect patient compliance. Acyclovir is poorly soluble in water and it requires formulation in a polyethylene glycol base 51, 52 .
A few side-effects has been linked to the topical use of Acyclovir with superficial punctate epithelial erosions being the commonest (9.8%) followed by burning or stinging on application of the ointment (4%) 53 . In order to compare the effectiveness of oral and topical acyclovir a study of sixty patients with simple dendritic corneal ulceration was conducted by Collum et al. The patients "were randomly assigned to double blind treatment with either acyclovir tablets (400 mg) or acyclovir ophthalmic ointment administered five times daily.
There was no significant difference in the proportions of patients healed in either treatment group (88.9% on oral acyclovir and 96.6% on acyclovir ointment). The median healing time was five days in both groups. No systemic or significant local side effects were noted in either treatment group." 54 The study concluded that "oral administration of acyclovir (400 mg, five times daily) may be an effective alternative to topical therapy in selected patients." Ganciclovir 0.15% ophthalmic preparation was found to be both safe and equally effective to acyclovir, however it has been postulated that ganciclovir resistance is much more rarely encountered and thus it could be used as an alternative in acyclovir-resistant cases; the topical formulation is well tolerated, nontoxic to the ocular surface, which could also be attributed to the hydrophilic nature of its formulation, and does not cause adverse systemic side effects. The most common adverse and toxic side effects are blurred vision, eye irritation, punctate keratitis, and conjunctival hyperemia and occur much less frequently compared with acyclovir 51, 52 .
Ocular pharmacokinetics
Topical acyclovir and ganciclovir "demonstrate effective penetration through the cornea to achieve therapeutic levels in deeper structures and the aqueous humor.
Its hydrophilic base allows ganciclovir to be solubilized as an aqueous gel. This enhances drug resorption, permitting equivalent therapeutic effects at far lower concentrations than that of acyclovir 3% ointment." 51 A single drop of ganciclovir gel on the ocular surface can produce tissue concentrations higher than the effective concentrations for HSV-1 and HSV-2 for over 4 hours. "This capacity to concentrate in ocular tissues and fluids could be related to continuous drug absorption over time because the gel formulation permits extended drug contact on the ocular surface. Ganciclovir gel has often been described as "galenic""," 51 a term used for a medication designed with maximal absorption properties.
Ganciclovir molecule is relatively small-sized with high lipophilicity and high cellular affinity. Increased lipophilicity enhances permeability through the corneal epithelium and the presence of an epithelial defect enhances corneal absorption by eliminating one of the primary barriers to absorption 51 .
CONCLUSION
Herpes simplex keratitis is an important cause of visual impairment and the pathogenesis of the different disease moieties remains elusive.
Current therapeutic practice remains founded upon the outcomes reported by the HEDS, the first large, randomized controlled study into the treatment of HSVK.
Newer medications such as valacyclovir however, which appears to have a superior therapeutic effect compared with acyclovir may provide a realistic treatment alternative for the future. The reduced frequency of dosage may aid compliance and the increased bioavailability may increase efficacy although the higher cost of valacyclovir may present a barrier to its use.
The "increasing use of ACV, especially in prophylaxis treatments among transplanted patients, has raised the fear of an increasing incidence of ACV-resistant infections.
Recent survey studies have shown that this is not the case and that ACV resistance is mainly a concern for severely immunocompromised patients, such as those transplanted with bone marrow from allogeneic origin. Notably, when managing ACV-resistant infections other antiviral drugs with different mechanisms of action may be used, such as foscarnet and cidofovir." 50 However, there is still increasing need, and research is ongoing, to develop new anti-herpetic compounds with different mechanisms of action which will be safe and effective against emerging drug-resistant viral strains.
In addition, "based on safety, efficacy, and tolerability, ganciclovir gel 0.15% is now considered the front-line topical antiviral drug for the treatment of dendritic herpes simplex epithelial keratitis. It exhibits less toxicity and offers a simpler dosing regimen than one of the main topical alternatives: trifluridine." 51 The American Academy of Ophthalmology supports the use of ganciclovir over topical acyclovir ointment despite similar healing rates. This appears to be linked to ganciclovir gel"s favorable side effect and tolerability profile. Furthermore, the difference in cost between the two topical agents may influence the choice of treatment 55 .
Based on our clinical experience and information in literature we propose an algorithm for the treatment of HSV in its different clinical presentations (Table 2 ).
Clinician"s preference and cost issues could potentially affect the decision for the type of treatment 56 .
There are several potential topics of interest for future research such as ganciclovir gel"s usefulness against HSV geographic ulcers, necrotizing keratitis and iridocyclitis.
Additionally, topical ganciclovir could be effective in adenoviral keratoconjunctivitis, CMV keratitis including endotheliitis, and herpes zoster ophthalmicus pseudodendritic keratitis. The clinical potential for this most recently developed topical antiviral agent, therefore, needs to be ascertained 51 .
Furthering the understanding of herpetic eye disease and promoting the development of more targeted therapy will undoubtedly alter our practice in the future and reduce the significant disease burden associated with this condition.
Finally, redesigning a new, third HED study, comparing various topical and oral antiviral agents could determine the optimal treatment regimen for herpetic eye disease with greater precision and concomitant generation of new information. 
HEDS II
No association was found between any of the variables and recurrence
No benefit from the addition of oral acyclovir to treatment with trifluridine in preventing stromal keratitis or iritis Oral acyclovir: a) Reduced by 41% the probability that any form of herpes of the eye would return in patients who had the infection in the previous year, b)
Reduced stromal recurrence by 50% among patients who had stromal keratitis in the past year, c) Reduced the incidence of epithelial keratitis from 11% to 9% and the incidence of stromal keratitis from 13% to 8%, d) 4% of patients in the acyclovir group and 9% in the placebo group had more than one recurrence
To determine whether early treatment of herpes simplex virus ulcerations of the corneal epithelium with oral acyclovir prevents progression to the blinding complications of stromal keratitis and iridocyclitis
To determine the efficacy of low-dose oral acyclovir in preventing recurrent HSV eye infection in patients with previous episodes of herpetic eye disease 
